- Home
- COUR vs IMCR Comparison
COUR vs IMCR Comparison
Compare COUR & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COUR
- IMCR
- Stock Information
- Founded
- COUR 2012
- IMCR 2008
- Country
- COUR United States
- IMCR United Kingdom
- Employees
- COUR N/A
- IMCR N/A
- Industry
- COUR Computer Software: Prepackaged Software
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COUR Technology
- IMCR Health Care
- Exchange
- COUR Nasdaq
- IMCR Nasdaq
- Market Cap
- COUR 1.8B
- IMCR 1.7B
- IPO Year
- COUR 2021
- IMCR 2021
- Fundamental
- Price
- COUR $9.81
- IMCR $34.26
- Analyst Decision
- COUR Buy
- IMCR Buy
- Analyst Count
- COUR 14
- IMCR 9
- Target Price
- COUR $11.59
- IMCR $57.00
- AVG Volume (30 Days)
- COUR 2.7M
- IMCR 287.1K
- Earning Date
- COUR 10-23-2025
- IMCR 11-05-2025
- Dividend Yield
- COUR N/A
- IMCR N/A
- EPS Growth
- COUR N/A
- IMCR N/A
- EPS
- COUR N/A
- IMCR N/A
- Revenue
- COUR $721,674,000.00
- IMCR $356,145,000.00
- Revenue This Year
- COUR $9.31
- IMCR $29.71
- Revenue Next Year
- COUR $5.64
- IMCR $11.27
- P/E Ratio
- COUR N/A
- IMCR N/A
- Revenue Growth
- COUR 7.10
- IMCR 26.78
- 52 Week Low
- COUR $5.76
- IMCR $23.15
- 52 Week High
- COUR $13.56
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- COUR 32.07
- IMCR 49.34
- Support Level
- COUR $11.43
- IMCR $33.92
- Resistance Level
- COUR $12.32
- IMCR $37.00
- Average True Range (ATR)
- COUR 0.47
- IMCR 1.45
- MACD
- COUR -0.20
- IMCR -0.06
- Stochastic Oscillator
- COUR 0.79
- IMCR 39.78
About COUR Coursera Inc.
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.